Abstract
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Current Pharmaceutical Design
Title: Inhibition of HIV-1 by Fusion Inhibitors
Volume: 16 Issue: 33
Author(s): Dirk Eggink, Ben Berkhout and Rogier W. Sanders
Affiliation:
Keywords: HIV, virus entry, antiviral peptide, fusion inhibitors, enfuvirtide, T20, VIRIP, resistance, HIV-1, envelope glycoprotein complex, human immunodeficiency virus type 1, gp41, gp120, Fuzeon, acquired immunodeficiency syndrome, Highly Active Antiretroviral Therapy (HAART), reverse transcriptase (RT), nucleoside analogue, non-nucleoside RT inhibitors, DNA strand elongation, zidovudine, stavudine, thymidine, didanosine, abacavir, guanine, viral Gag, Gag-Pol precursor, Saquinavir, ritonavir, indinavir, integrase, Maraviroc, BMS-378806, PRO542, immunoglobulin, vicriviroc, coronaviridae, TORO phase III study, HXB2 isolate, S138A, N126K, Cyclic depsipeptides, Siliquaria spongia mirabilis
Abstract: The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Receptor antagonists prevent attachment of gp120 to the receptor or co-receptor and conformational changes within gp41 required for membrane fusion can be inhibited by fusion inhibitors. Enfuvirtide (T20, Fuzeon) is a peptide based on the gp41 sequence and is the only approved fusion inhibitor. It prevents membrane fusion by competitively binding to gp41 and blocking the formation of the post-fusion structure. New generations of T20-like peptides have been developed with improved potency and stability. Besides T20 and derivatives, other fusion inhibitors have been developed that target different domains of gp41. Here we discuss the development of fusion inhibitors, their mode of action and their potential for incorporation in future drug regimens.
Export Options
About this article
Cite this article as:
Eggink Dirk, Berkhout Ben and W. Sanders Rogier, Inhibition of HIV-1 by Fusion Inhibitors, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079218
DOI https://dx.doi.org/10.2174/138161210794079218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Ocular Immune Responses by Corneal Epithelium
Current Immunology Reviews (Discontinued) Cancer Cell Cannibalism: A Primeval Option to Survive.
Current Molecular Medicine Arthritis and Periodontitis: An Association Debated for Over Two Centuries
Current Rheumatology Reviews Telomere End Protection in Stem Cells and Cancer Cells
Current Cancer Therapy Reviews GluVII:06 - A Highly Conserved and Selective Anchor Point for Non-Peptide Ligands in Chemokine Receptors
Current Topics in Medicinal Chemistry The Pharmacokinetics and Toxicology of Aluminum in the Brain
Current Inorganic Chemistry (Discontinued) Role of Neuroimaging Modality in the Assessment of Oxidative Stress in Brain: A Comprehensive Review
CNS & Neurological Disorders - Drug Targets The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Epidemiology, Evolution, Transmission, and Therapeutics of COVID-19 Outbreak: An Update on the Status
Coronaviruses Fructo-oligosaccharides Ameliorate Intestinal Mechanical Barrier Injury in Piglets Induced by Soybean Antigen <i>in vitro</i> and <i>in vivo</i>
Current Protein & Peptide Science Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Synthetic Lipoproteins as Carriers for Drug Delivery
Current Medicinal Chemistry HIV-1-Associated Dementia During HAART Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Matrix Metalloproteinases in Acute Inflammatory Shock Syndromes
Combinatorial Chemistry & High Throughput Screening Canine Nutritional Model: Influence of Age, Diet, and Genetics on Health and Well-Being
Current Nutrition & Food Science Recent Developments in Anxiety Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Diet and the Anti-inflammatory Effect of Heat Shock Proteins
Endocrine, Metabolic & Immune Disorders - Drug Targets Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry